Hefei Lifeon Pharmaceutical Co Ltd (003020) - Total Assets
Based on the latest financial reports, Hefei Lifeon Pharmaceutical Co Ltd (003020) holds total assets worth CN¥2.60 Billion CNY (≈ $380.12 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Hefei Lifeon Pharmaceutical Co Ltd net assets for net asset value and shareholders' equity analysis.
Hefei Lifeon Pharmaceutical Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Hefei Lifeon Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Hefei Lifeon Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hefei Lifeon Pharmaceutical Co Ltd's total assets of CN¥2.60 Billion consist of 45.8% current assets and 54.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.0% |
| Accounts Receivable | CN¥423.70 Million | 16.4% |
| Inventory | CN¥220.48 Million | 8.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥108.31 Million | 4.2% |
| Goodwill | CN¥74.44 Million | 2.9% |
Asset Composition Trend (2012–2024)
This chart illustrates how Hefei Lifeon Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hefei Lifeon Pharmaceutical Co Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hefei Lifeon Pharmaceutical Co Ltd's current assets represent 45.8% of total assets in 2024, a decrease from 71.4% in 2012.
- Cash Position: Cash and equivalents constituted 17.0% of total assets in 2024, up from 13.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 2.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 16.4% of total assets.
Hefei Lifeon Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Hefei Lifeon Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Hefei Lifeon Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.15 | 3.77 |
| Quick Ratio | 1.71 | 1.76 | 3.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥651.01 Million | CN¥620.21 Million | CN¥949.61 Million |
Hefei Lifeon Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hefei Lifeon Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.60 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 4.1% |
| Total Assets | CN¥2.59 Billion |
| Market Capitalization | $632.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hefei Lifeon Pharmaceutical Co Ltd's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hefei Lifeon Pharmaceutical Co Ltd's assets grew by 4.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hefei Lifeon Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual total assets of Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.59 Billion ≈ $378.41 Million |
+4.12% |
| 2023-12-31 | CN¥2.48 Billion ≈ $363.44 Million |
+17.06% |
| 2022-12-31 | CN¥2.12 Billion ≈ $310.48 Million |
+26.71% |
| 2021-12-31 | CN¥1.67 Billion ≈ $245.02 Million |
+9.01% |
| 2020-12-31 | CN¥1.54 Billion ≈ $224.77 Million |
+72.62% |
| 2019-12-31 | CN¥889.81 Million ≈ $130.21 Million |
+15.41% |
| 2018-12-31 | CN¥771.01 Million ≈ $112.82 Million |
+25.81% |
| 2017-12-31 | CN¥612.85 Million ≈ $89.68 Million |
+11.87% |
| 2016-12-31 | CN¥547.80 Million ≈ $80.16 Million |
+15.17% |
| 2014-12-31 | CN¥475.64 Million ≈ $69.60 Million |
+6.59% |
| 2013-12-31 | CN¥446.22 Million ≈ $65.30 Million |
+24.42% |
| 2012-12-31 | CN¥358.64 Million ≈ $52.48 Million |
-- |
About Hefei Lifeon Pharmaceutical Co Ltd
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethy… Read more